Drug
Pemetrexed clinical trials
Also written Alimta, LY231514, Pemfexy and NSC-698037.
- studies test it
- 524
- open now
- 73
- in phase 3
- 78
- first study started
- 1998
Keep track of what changes. Save the Pemetrexed studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
- Pemetrexed
- 335
- MTA
- 31
Development codes
- LY231514
- 84
Studies by the year they started
509 studies that test it; most in 2006 (53); 1 more planned to start later
| Year | Studies |
|---|---|
| 1998 | 1 |
| 1999 | 1 |
| 2001 | 2 |
| 2002 | 3 |
| 2003 | 12 |
| 2004 | 17 |
| 2005 | 46 |
| 2006 | 53 |
| 2007 | 28 |
| 2008 | 30 |
| 2009 | 29 |
| 2010 | 17 |
| 2011 | 11 |
| 2012 | 15 |
| 2013 | 15 |
| 2014 | 9 |
| 2015 | 18 |
| 2016 | 10 |
| 2017 | 21 |
| 2018 | 18 |
| 2019 | 19 |
| 2020 | 23 |
| 2021 | 19 |
| 2022 | 25 |
| 2023 | 19 |
| 2024 | 23 |
| 2025 | 13 |
| 2026 | 12 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 4
- Phase 1
- 123
- Phase 2
- 355
- Phase 3
- 78
- Phase 4
- 15
- No phase
- 12
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 187 · Other 337
Eli Lilly and Company (97) · Sun Yat-sen University (12) · National Cancer Institute (NCI) (10) · M.D. Anderson Cancer Center (10) · AstraZeneca (9) · Alliance for Clinical Trials in Oncology (8) · Hunan Province Tumor Hospital (8) · Hoffmann-La Roche (7)
Often tested with
Tested in the same studies.
Carboplatin (150) · Cisplatin (138) · Gemcitabine (63) · Bevacizumab (55) · Paclitaxel (49) · Docetaxel (37) · Pembrolizumab (22) · Erlotinib (20)
Studies
Open first, then newest update. How each study uses Pemetrexed is read from its arms, and is right about nine times in ten.
Testing it · 524
- Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE TrialRecruitingPhase 3National Cancer Institute (NCI)NCT06096844Written as Pemetrexed
- MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLCNot yet recruitingPhase 2Peking University People's HospitalNCT07885709Written as Pemetrexed
- Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung CancerRecruitingPhase 2AstraZenecaNCT05061550Written as Pemetrexed/Cisplatin
- Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic AlterationsRecruitingPhase 1/2AbbVieNCT06772623Written as Pemetrexed
- Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCRecruitingPhase 1/2Revolution Medicines, Inc.NCT06162221Written as Pemetrexed
- PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50%Not yet recruitingPhase 3German Cancer Research CenterNCT07877584Written as Pemetrexed (500 mg/m²)
- Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)RecruitingPhase 2/3BioNTech SENCT06712316Written as Pemetrexed
- A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerNot yet recruitingPhase 2/3Shanghai Henlius BiotechNCT07865910Written as Pemetrexed (1)
- A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerRecruitingPhase 3Eli Lilly and CompanyNCT06119581Written as Pemetrexed
- A Platform Study in Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 1/2AstraZenecaNCT06996782Written as Pemetrexed
- Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLCRecruitingPhase 3Stanford UniversityNCT04585490Written as Pemetrexed
- This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation.Not yet recruitingPhase 1/2Genfleet Therapeutics (Shanghai) Inc.NCT07846358Written as Pemetrexed
- Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/ImmunotherapyRecruitingPhase 2Wake Forest University Health SciencesNCT04253964Written as Pemetrexed
- A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal MesotheliomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06057935Written as Pemetrexed
- Pan Tumor Rollover StudyRecruitingPhase 2Bristol-Myers SquibbNCT03899155Written as Pemetrexed
- A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerNot yet recruitingPhase 3Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT07822542Written as Pemetrexed
- BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP DeletionRecruitingPhase 1/2Northwestern UniversityNCT07594626Written as Pemetrexed
- Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS LymphomasNot yet recruitingPhase 1Allison WinterNCT07608731Written as Pemetrexed
- A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain MetastasesRecruitingPhase 3Allist Pharmaceuticals, Inc.NCT06970639Written as Pemetrexed Disodium for Injection
- A Study of DS-3939a in Participants With Solid TumorsNot yet recruitingPhase 1/2Daiichi SankyoNCT07739966Written as Pemetrexed
See all 524 studies that test Pemetrexed →
Given in every arm · 393 — Pemetrexed is usual care beside what is tested
- Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])RecruitingPhase 3National Cancer Institute (NCI)NCT04267848Written as Pemetrexed Disodium
- A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%RecruitingPhase 3Bristol-Myers SquibbNCT06561386Written as Pemetrexed
- A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid TumorsRecruitingPhase 1/2Verastem, Inc.NCT07020221Written as Carboplatin + Pemetrexed + Pembrolizumab
- Study of GS-5319 Given Alone or in Combination in Adults With Solid TumorsRecruitingPhase 1Gilead SciencesNCT07128303Written as Pemetrexed
- A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP DeletionRecruitingPhase 2/3Bristol-Myers SquibbNCT07063745Written as Pemetrexed
- A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 2Bristol-Myers SquibbNCT07680764Written as Pemetrexed
- Immune Checkpoint Blockade and Chemotherapy With or Without Fecal Microbiota Transplant in Advanced Non-Small Cell Lung CancerNot yet recruitingPhase 2Canadian Cancer Trials GroupNCT07890493Written as pemetrexed
- A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.RecruitingPhase 2/3Eikon TherapeuticsNCT07365319Written as Pemetrexed + Cisplatin /Carboplatin
- CR-001 in Adult Participants With Locally Advanced or Metastatic Solid TumorsRecruitingPhase 1/2Crescent Biopharma, Inc.NCT07335497Written as Pemetrexed
- Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLCRecruitingPhase 2CatalYm GmbHNCT07098988Written as Pemetrexed 500 mg/m^2
- A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06623422Written as Pemetrexed
- A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) MutationRecruitingPhase 1Kestrel Therapeutics, Inc.NCT07458347Written as Pemetrexed
- MRD-Guided Aumolertinib-Based Adjuvant Therapy for Resected EGFR-Mutant NSCLCNot yet recruitingNot applicablePeking University People's HospitalNCT07873086Written as Pemetrexed
- A Study of ASP3082 in Adults With Advanced Solid TumorsRecruitingPhase 1Astellas Pharma IncNCT05382559Written as Pemetrexed
- A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)Not yet recruitingPhase 2Bristol-Myers SquibbNCT07871214Written as Pemetrexed
- A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)RecruitingPhase 3Mirati Therapeutics Inc.NCT06875310Written as Pemetrexed
- A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib StudiesRecruitingPhase 2Mirati Therapeutics Inc.NCT07415031Written as Pemetrexed
- A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)Not yet recruitingPhase 2Merck Sharp & Dohme LLCNCT07793942Written as Pemetrexed
- A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)RecruitingPhase 1Merck Sharp & Dohme LLCNCT05067283Written as pemetrexed
- A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C MutationRecruitingPhase 1/2Hoffmann-La RocheNCT05789082Written as Pemetrexed
Showing 20 of 393.
As the comparator · 110 — what is tested is compared with Pemetrexed
- Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung CancerRecruitingPhase 3Daiichi SankyoNCT06899126Written as Pemetrexed
- A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)RecruitingPhase 2Merck Sharp & Dohme LLCNCT06731907Written as Pemetrexed
- A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)RecruitingPhase 3BayerNCT06452277Written as Pemetrexed
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06312137Written as Pemetrexed
- Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)RecruitingPhase 2/3Bristol-Myers SquibbNCT07100080Written as Pemetrexed
- Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)RecruitingPhase 3Bristol-Myers SquibbNCT07680790Written as Pemetrexed
- A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07190248Written as Pemetrexed
- A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerRecruitingPhase 3Hoffmann-La RocheNCT06793215Written as Pemetrexed
- A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C MutationNot yet recruitingPhase 3Shanghai Jeyou Pharmaceutical Co., Ltd.NCT07833202Written as Tislelizumab + Carboplatin + Pemetrexed
- Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic AlterationsNot yet recruitingPhase 3RemeGen Co., Ltd.NCT07829549Written as Tislelizumab Injection plus Pemetrexed Disodium for Injection and Carboplatin Injection
- JSKN033 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical CancerNot yet recruitingPhase 3Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT07797153Written as Pemetrexed
- A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06)Not yet recruitingPhase 2/3Sichuan Baili Pharmaceutical Co., Ltd.NCT07739186Written as Pemetrexed
- ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI TherapyRecruitingPhase 3Jiangsu Aosaikang Pharmaceutical Co., Ltd.NCT07109531Written as Pemetrexed + Cisplatin /Carboplatin
- JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C MutationRecruitingPhase 3Allist Pharmaceuticals, Inc.NCT06416410Written as Pemetrexed
- Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q MutationRecruitingPhase 3Allist Pharmaceuticals, Inc.NCT06956001Written as Pemetrexed Disodium for Injection
- Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung DiseaseNot yet recruitingPhase 2Intergroupe Francophone de Cancerologie ThoraciqueNCT07420439Written as Pemetrexed
- A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)RecruitingPhase 2/3Sichuan Baili Pharmaceutical Co., Ltd.NCT07642024Written as Pemetrexed
- Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）RecruitingPhase 3CSPC Megalith Biopharmaceutical Co.,Ltd.NCT06927986Written as Pemetrexed
- A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical CancerRecruitingPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07418749Written as Pemetrexed Disodium for Injection
- Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung CancerRecruitingPhase 2Gustave Roussy, Cancer Campus, Grand ParisNCT07001618Written as Pemetrexed (Alimta)
Showing 20 of 110.
Codes
What other systems call Pemetrexed · ClinicalTrials.gg INT006512
- MeSH (NLM) D000068437PemetrexedConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 04Q9AIZ7NOPEMETREXEDConfirmed FDA, NLM, Wikidata
- RxNorm 68446Confirmed FDA, Wikidata
- Wikidata Q415220pemetrexedConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C61614PemetrexedOne source FDA
- DrugBank DB00642One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000068437 | Pemetrexed | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 04Q9AIZ7NO | PEMETREXED | Confirmed FDA, NLM, Wikidata |
| RxNorm | 68446 | — | Confirmed FDA, Wikidata |
| Wikidata | Q415220 | pemetrexed | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C61614 | Pemetrexed | One source FDA |
| DrugBank | DB00642 | — | One source Wikidata |
Also registered as pemetrexed disodium (UNII 2PKU919BA9 · RxNorm 282443).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.